Clinical Trial

AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a phase 3 study. All subjects are patients with unresectable locally advanced or metastatic biliary tract cancer (BTC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in combination with chemotherapy versus durvalumab in combination with chemotherapy in patients with unresectable locally advanced or metastatic BTC.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-08.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-01-19
Trial Details
NCT Number NCT06591520
Lead Sponsor Akeso
Conditions Biliary Tract Cancer
Enrollment 682 participants
Start Date 2024-10-20
Primary Completion 2026-10 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-21